CD274 and lung carcinoma: It acts as a prognostic biomarker for treatment with ICIs, where significant decreases in ctDNA levels are associated with benefits from immunotherapy and longer survival in lung cancer patients receiving anti-PD-1/PD-L1 therapies [230].